Cargando…
Applying science in practice: the optimization of biological therapy in rheumatoid arthritis
Most authorities recommend starting biological agents upon failure of at least one disease-modifying agent in patients with rheumatoid arthritis. However, owing to the absence of head-to-head studies, there is little guidance about which biological to select. Still, the practicing clinician has to d...
Autores principales: | Ramiro, Sofia, Machado, Pedro, Singh, Jasvinder A, Landewé, Robert B, da Silva, José António P |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3046505/ https://www.ncbi.nlm.nih.gov/pubmed/21067530 http://dx.doi.org/10.1186/ar3149 |
Ejemplares similares
-
Discontinuation rates of biologics in patients with rheumatoid arthritis: are TNF inhibitors different from non-TNF inhibitors?
por: Ramiro, Sofia, et al.
Publicado: (2015) -
Association of the different types of radiographic damage with physical function in patients with rheumatoid arthritis: analysis of the RAPID trials
por: Gherghe, Ana Maria, et al.
Publicado: (2016) -
Evaluating patient reported outcomes in routine practice of patients with rheumatoid arthritis treated with biological disease modifying anti rheumatic drugs (b-DMARDs)
por: Boone, Niels W., et al.
Publicado: (2015) -
Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis
por: Gaujoux-Viala, Cécile, et al.
Publicado: (2014) -
Summary of AHRQ’s Comparative Effectiveness Review of Drug Therapy for Rheumatoid Arthritis (RA) in Adults – An Update
por: Singh, Jasvinder A., et al.
Publicado: (2012)